spacer
home > ebr > summer 2003 > perspectives in preclinical development
PUBLICATIONS
European Biopharmaceutical Review

Perspectives in Preclinical Development

Pharmaceutical companies have traditionally outsourced a proportion of their preclinical development studies to contract research laboratories. This co-operation can be traced back to the mid-sixties and the proliferation of regulatory guidelines which followed the thalidomide disaster earlier that decade. At that time, the international requirements for protocol-driven toxicity studies for new pharmaceuticals put a strain on the resources of many drug companies.

The answer for many was to outsource individual studies to the rapidly-evolving contract research industry, pioneered by companies such as Huntingdon Research Centre in England and Inveresk Research in Scotland. These organisations turned their focus from experimental nutrition studies to the toxicity testing of drugs and other chemicals.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Thomas Allen, Director of Allen Preclinical Consultants GmbH

Thomas Allen is a Director of Allen Preclinical Consultants GmbH, based in Switzerland. His career has spanned more than 25 years with European CROs and pharmaceutical companies, most recently with RCC Ltd where he was a member of the Executive Committee and, for many years, Director of Toxicology.

Thomas has a degree in Zoology and Physiology from the University of Sheffield and is a Diplomate of the Royal College of Pathologists and a European Registered Toxicologist.

spacer
Thomas Allen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Ypsomed and Dexcom enter into partnership to drive closed loop system

Burgdorf/San Diego – Ypsomed (SWX:YPSN) and DexCom Inc. (NASDAQ:DXCM), the world's leading provider of continuous glucose monitoring (CGM) systems, announce their partnership to drive development of a hybrid closed loop system. The partnership is an important milestone in the further development of individualised diabetes therapy. In a first step, CGM data from Dexcom will be integrated into the mylife™ App from Ypsomed.
More info >>

White Papers

ConsulTech GmbH

ConsulTech GmbH

ConsulTech is a consulting company founded in 1992. Since then, we have been supporting biotech-nology, pharmaceutical and medical technology companies as well as research institutions with the entire process of setting-up and executing proposals for R&D projects. In projects funded by the European Commission, ConsulTech supports the coordinator by resuming administrative tasks allow-ing coordinators and partners to fully concentrate on the scientific and technical success of the pro-ject. We solve financial and administrative issues, organise meetings, take care of the timely delivery of milestones and reports and much more.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement